Harnessing the power of RNA modification

Watch full video

1st in Class Inhibitors of RNA Modifying Enzymes (RME) with the potential to Treat Cancer and Other Diseases

STORM Therapeutics (STORM) a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.

Read more

RNA modifying enzymes

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template to which transfer RNAs (tRNA) bind to drive the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more

News

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

The Medicine Maker: The Power List 2024

Events

There are no upcoming events